April 11 (Reuters) - Swiss drugmaker Novartis AG has entered into a licensing deal worth up to $1.01 billion with Arvinas for the U.S. drug developer's experimental prostate cancer drug, Arvinas said on Thursday. (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.43 USD | -0.15% | +2.63% | -21.21% |
Apr. 24 | Arvinas, Inc. Appoints Randy Teel as Chief Business Officer | CI |
Apr. 15 | H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
88.54 CHF | -0.37% | -0.33% | 199B | ||
32.43 USD | -0.15% | +2.63% | 2.22B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.21% | 2.22B | |
-1.65% | 103B | |
+6.75% | 101B | |
+6.87% | 23.07B | |
-12.60% | 22.23B | |
-5.48% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- ARVN Stock
- News Arvinas, Inc.
- Novartis licenses Arvinas' cancer drug for up to $1 billion